ADAR1 Capital Management LLC Acquires 483,244 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

ADAR1 Capital Management LLC lifted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 16.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 3,508,694 shares of the company’s stock after buying an additional 483,244 shares during the quarter. Roivant Sciences comprises about 8.3% of ADAR1 Capital Management LLC’s portfolio, making the stock its 2nd largest holding. ADAR1 Capital Management LLC’s holdings in Roivant Sciences were worth $41,508,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Russell Investments Group Ltd. increased its position in Roivant Sciences by 478.6% during the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock worth $28,000 after buying an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd acquired a new stake in Roivant Sciences in the 4th quarter worth about $39,000. GAMMA Investing LLC grew its position in shares of Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after purchasing an additional 1,507 shares during the period. Finally, Quarry LP grew its position in Roivant Sciences by 50.0% during the third quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after buying an additional 2,500 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Price Performance

NASDAQ ROIV opened at $9.46 on Monday. The stock has a market capitalization of $6.75 billion, a P/E ratio of -63.06 and a beta of 1.25. The business has a 50 day simple moving average of $10.62 and a 200 day simple moving average of $11.32. Roivant Sciences Ltd. has a one year low of $9.42 and a one year high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Equities analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Analyst Ratings Changes

ROIV has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th.

Insider Buying and Selling

In other Roivant Sciences news, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the stock in a transaction on Monday, January 13th. The shares were purchased at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the acquisition, the director now owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. This represents a 21.11 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Eric Venker sold 434,478 shares of Roivant Sciences stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $10.82, for a total transaction of $4,701,051.96. Following the transaction, the chief operating officer now owns 1,127,290 shares of the company’s stock, valued at $12,197,277.80. This represents a 27.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,395,541 shares of company stock valued at $15,028,538. 7.90% of the stock is owned by company insiders.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.